全文获取类型
收费全文 | 504篇 |
免费 | 32篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 17篇 |
妇产科学 | 11篇 |
基础医学 | 41篇 |
口腔科学 | 18篇 |
临床医学 | 68篇 |
内科学 | 104篇 |
皮肤病学 | 17篇 |
神经病学 | 4篇 |
特种医学 | 127篇 |
外科学 | 29篇 |
综合类 | 12篇 |
预防医学 | 34篇 |
眼科学 | 6篇 |
药学 | 18篇 |
中国医学 | 2篇 |
肿瘤学 | 40篇 |
出版年
2023年 | 2篇 |
2022年 | 3篇 |
2021年 | 8篇 |
2020年 | 2篇 |
2019年 | 4篇 |
2018年 | 14篇 |
2017年 | 4篇 |
2016年 | 8篇 |
2015年 | 12篇 |
2014年 | 8篇 |
2013年 | 25篇 |
2012年 | 14篇 |
2011年 | 10篇 |
2010年 | 14篇 |
2009年 | 28篇 |
2008年 | 8篇 |
2007年 | 26篇 |
2006年 | 15篇 |
2005年 | 15篇 |
2004年 | 4篇 |
2003年 | 5篇 |
2002年 | 5篇 |
2001年 | 9篇 |
2000年 | 2篇 |
1999年 | 8篇 |
1998年 | 48篇 |
1997年 | 45篇 |
1996年 | 23篇 |
1995年 | 23篇 |
1994年 | 12篇 |
1993年 | 12篇 |
1992年 | 2篇 |
1991年 | 6篇 |
1990年 | 8篇 |
1989年 | 11篇 |
1988年 | 15篇 |
1987年 | 15篇 |
1986年 | 13篇 |
1985年 | 10篇 |
1984年 | 9篇 |
1983年 | 8篇 |
1982年 | 6篇 |
1981年 | 6篇 |
1980年 | 10篇 |
1979年 | 3篇 |
1977年 | 3篇 |
1976年 | 2篇 |
1975年 | 6篇 |
排序方式: 共有549条查询结果,搜索用时 0 毫秒
51.
Miriam Hoekstra Mathijs Vogelzang José T Drost Marcel Janse Bert G Loef Iwan CC van der Horst Felix Zijlstra Maarten WN Nijsten 《BMC medical informatics and decision making》2010,10(1):5
Background
Potassium disorders can cause major complications and must be avoided in critically ill patients. Regulation of potassium in the intensive care unit (ICU) requires potassium administration with frequent blood potassium measurements and subsequent adjustments of the amount of potassium administrated. The use of a potassium replacement protocol can improve potassium regulation. For safety and efficiency, computerized protocols appear to be superior over paper protocols. The aim of this study was to evaluate if a computerized potassium regulation protocol in the ICU improved potassium regulation. 相似文献52.
53.
BACKGROUND: Complicated intra-abdominal infections (cIAIs) require surgical intervention and empiric antibacterial therapy. Doripenem, a broad-spectrum carbapenem, provides coverage of key gram-negative and -positive aerobes and anaerobes encountered in cIAI. OBJECTIVE: This study was designed to compare the efficacy and safety profile of doripenem and meropenem in hospitalized adult patients with cIAI. METHODS: In this prospective, multicenter, doubleblind, noninferiority study, hospitalized adults with cIAI were randomly assigned to receive doripenem 500 mg IV q8h or meropenem 1 g IV q8h. After a minimum of 9 doses and adequate clinical improvement (relative to before the start of IV study drug, decreased body temperature and white blood cell count, improved or absent signs and symptoms of cIAI, and return of normal bowel function), patients could be switched to oral amoxicillin/clavulanate. Antibacterial therapy (IV plus subsequent oral) was given for a total of 5 to 14 days. The coprimary efficacy end points were the clinical cure rate (complete resolution or significant improvement of signs or symptoms of the index infection) in patients microbiologically evaluable (>or=1 baseline pathogen isolated from an intra-abdominal culture that was susceptible to both IV study drug therapies) at the test-of-cure (TOC) visit (21-60 days after the completion of study drug therapy) and the clinical cure rate in the microbiological modified intent-to-treat (mMITT) population (a bacterial pathogen identified at baseline, regardless of its susceptibility to the study drug). Noninferiority was concluded if the lower limit of the 2-sided 95% CI for the difference (doripenem minus meropenem) in the proportion of patients classified as clinical cures was >or=-15%. RESULTS: A total of 476 patients were enrolled. The microbiologically evaluable population (319 patients) was 62.7% male and 67.7% white, with a mean age and weight of 46.7 years and 77.2 kg, respectively. In this population, doripenem and meropenem were associated with clinical cure rates at the TOC visit of 85.9% and 85.3%, respectively. The corresponding treatment difference was 0.6% (95% CI, -7.7% to 9.0%); this difference was not statistically significant. Similarly, in the mMITT population (385 patients), the clinical cure rates were 77.9% and 78.9%, respectively, and the corresponding 1.0% treatment difference was not statistically significant (95% CI, -9.7% to 7.7%). Clinical cure rates were not significantly different between the 2 treatment arms in key subgroups (eg, age, sex, race, baseline Acute Physiology and Chronic Health Evaluation II score, primary infection site). Microbiological eradication rates for common pathogens isolated at study entry were not significantly different between the 2 treatment groups. Doripenem was well tolerated in the population studied. In the intent-to-treat population (471 patients), 83.0% and 78.0% of patients experienced >or=1 adverse event (AE) and 13.2% and 14.0% experienced >or=1 serious AE in the doripenem and meropenem treatment arms, respectively. In the doripenem and meropenem treatment arms, AEs resulted in study drug discontinuation in 5.1% and 2.1% of patients and death in 2.1% and 3.0% of patients, respectively. CONCLUSIONS: The present study found that doripenem (500 mg q8h) was effective in the treatment of cIAI, was therapeutically noninferior to meropenem (1 g q8h), with a safety profile not significantly different from that of meropenem in this selected population of patients with cIAI. 相似文献
54.
YL Cheng CC Shek FK Wong KS Choi KF Chau TS Ing CS Li 《American journal of kidney diseases》1998,31(6):986-990
In 22 hemodialysis patients, during a dialysis session, the solute removal index (SRI) for urea obtained from the use of a partial spent dialysate collection method was compared with that derived from the use of a total spent dialysate collection technique. The partial spent dialysate collection method was used to harvest a small representative sample of the total spent dialysate. The volumes of spent dialysate collected by the partial and the total spent dialysate collection methods were 1.7 +/- 0.4 L and 129.6 +/- 15.3 L, respectively. The total amount of urea nitrogen removed by dialysis as estimated by the partial spent dialysate collection method was similar to that determined by the total spent dialysate collection approach. As a result, the SRI value for urea obtained by the partial spent dialysate collection method (namely, 63% +/- 8%) correlated very well (r = 0.95, P < 0.001) with that derived by the total spent dialysate collection technique (namely, 62% +/- 8%). Our data suggest that it is feasible to use a simple partial spent dialysate collection method to obtain SRI results in patients treated with hemodialysis. 相似文献
55.
56.
57.
Takenoshita S; Hagiwara K; Gemma A; Nagashima M; Ryberg D; Lindstedt BA; Bennett WP; Haugen A; Harris CC 《Carcinogenesis》1997,18(7):1427-1429
The transforming growth factor-beta type II receptor (RII) is commonly
mutated in colon and gastric cancers with microsatellite instability (MI).
We utilized our series of lung cancers with MI and rare alleles of the
H-ras1 gene to determine the association between MI and RII mutations and
searched the entire RII coding region in 33 lung cancers with MI by
polymerase chain reaction-single-strand conformation polymorphism analysis.
We found no mutations, and these data support other recent evidence that
RII mutations rarely occur except in colon and gastric tumors with MI.
相似文献
58.
59.
Background
Pneumocystis jiroveci pneumonia (PCP) is an important opportunistic infection among immunosuppressed patients, especially in those infected with human immunodeficiency virus (HIV). The clinical presentation of PCP in immunosuppressed patients have been well-reported in the literature. However, the clinical importance of PCP manifesting in the setting of an immunorestitution disease (IRD), defined as an acute symptomatic or paradoxical deterioration of a (presumably) preexisting infection, which is temporally related to the recovery of the immune system and is due to immunopathological damage associated with the reversal of immunosuppressive processes, has received relatively little attention until recently. 相似文献60.
The effect of fibrin polymers on thrombin-catalyzed factor XIIIa formation was studied in afibrinogenemic plasma. Fibrin polymers derived from des A fibrinogen and des A,B fibrinogen increased sixfold the rate of thrombin-catalyzed factor XIIIa formation in the presence of EDTA. Calcium chloride accelerated factor XIIIa formation 14-fold in the presence of des A,B fibrinogen without increasing the rate of thrombin formation. Fibrinopeptides A and B had no effect on factor XIIIa formation in afibrinogenemic plasma. Des A,B fibrinogen reduced by 20- to 40-fold the thrombin concentration required to activate factor XIII. Glycyl-L-prolyl-L-arginyl-L-proline (gly-pro-arg-pro), a fibrin polymerization inhibitor, inhibited des A and des A,B fibrinogen from enhancing thrombin-catalyzed factor XIIIa formation. Gly-pro-arg- pro did not modify factor XIIIa formation in afibrinogenemic plasma and did not inhibit thrombin cleavage of the chromogenic substrate S-2238. These results demonstrate that fibrin polymers accelerate thrombin- catalyzed plasma factor XIIIa formation. 相似文献